Prof. Nina
Khanna Gremmelmaier, MD
Position(s)
Leading Senior Physician, Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel
Research Group Leader, Department of Biomedicine Infection Biology, University of Basel
Institution
University Hospital Basel
Phone +41 61 328 73 25
Research Group Nina Khanna Gremmelmaier
Research Focus
Immunology & Infectious Diseases
Area of Research
Viral and fungal infections, especially in immunocompromised patients. Evaluation of new immune biomarkers and new immunotherapeutic strategies
Approved Research Projects
- 2021 – 2025 Epstein-Barr Virus-specific T Memory Stem Cell Therapy to Treat EBV-driven Lymphomas/Diseases, first trial with adoptive transfer of antigen-specific T memory stem cells for EBV-specific T-cell therapy; insights into fate of these cells after infusion into patients
- 2021 – 2024 University Hospital of Basel: Innovation Focus Cell Therapy
- 2021 Propatient Research Grant: Third-Party Donor Registry for Personalized antiviral T-cell Immunotherapeutics
- 2020 – 2024 Swiss National Science Foundation. National Center of Competence in Research (NCCR) AntiResist
- 2018 Bangerter–Rhyner Grant: A Phase I/II single-center study to assess safety and feasibility of virus-specific T cells of 3rd party donors in patients with treatment-refractory viral infections
- 2018 – 2022 Project Partner Swiss National Science Foundation. Investigator Initiated Clinical Trials (IICT): Using Genetic Risk Factors to Stratify Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia
- 2018 Debiopharm International S.A: Evaluation of Debio 1450 against 24-h biofilm in mouse tissue cage model (combination with: nafcillin, cefazolin, clindamycin, linezolid)
- 2017 Bangerter–Rhyner Grant: Immune-metabolic changes in neutrophils, monocytes and lymphocytes in patients suffering from gram-negative sepsis
- 2016 Swiss Transplant Cohort Study. Evolution of mold-specific T cells and NK cells and impact of T-helper 1 Cytokine and Natural Killer (NK) Cell Candidate Genes and on the Development and Outcome of Invasive Mold Infections in Patients after Allogeneic Hematopoietic Stem Cell Transplantation
- 2013 Commission for Technology and Innovation CTI: "HIT to LEAD to preclinical candidate development of a transcription repressor inhibitory compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci”
- 2013 Swiss National Science Foundation: Relevance of different CD4+ T cell subsets for antifungal defense. What is aberrant in immunocompromised patients?
Collaborations
National Collaborations
- 2021 – present ESP Working Group, Medical Faculty, University of Basel
- 2020 – present Scientific Advisory Committee, Propatient – Research Foundation, University Hospital Basel
- 2020 – present Structural Commission for Professorship of Hematology Stem Cell Research, University of Basel
- 2020 – present Appeals Committee for Professorship of the Clinical Epidemiology, University of Basel
- 2019 – present Leader of Clinical Studies and Member of executive board of National Center of Competence in Research (NCCR) AntiResist
- 2018 – present Subcommission for the Promotion of Young Researchers (= SK2), University of Basel
- 2017 – present Swisstransplant Arbeitsgruppe Infektiologie (STAI), representative from the USB
- 2016 – present Scientific Advising for the Swiss Society for Infectious Diseases
- 2014 – present Advisory boards on Anti-infectives for Pfizer, Switzerland
- 2013 – present Advisory boards on Anti-infectives for Merck Sharp Dohme, Switzerland
- 2010 – present Fungal Infection Network of Switzerland (FUNGINOS); President since 2021
- 2008 – present Infectious Diseases Working Group, Swiss Transplant cohort Study (STCS)
- 2014 – 2018 Steering Committee of the University Basel Immunology Community (UBICO)
- 2008 – present Schweizerische Gesellschaft für Infektiologie (SGINF)
- 2001 – present Schweizerische Medizinische Gesellschaft (FMH)
- 2021– present Management Team Innovation Focus Cell Therapy
International Collaborations
- 2018 – present ESCMID Study Group for Immunocompromised Hosts
- 2018 – present ESCMID Study Group Fungal Infection Study Group
- 2018 – present Member of Data safety montoring board for Allecra Therapeutics SAS, France
- 2017 – present Consultancy on respiratory infection research for Janssen Pharmaceuticals
- 2014 – present Advisory boards on Antifungals for Gilead Science, DACH (Germany, Austria, CH)
- 2013 – present European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Ongoing Research Projects
- 2021 – 2025 Epstein-Barr Virus-specific T Memory Stem Cell Therapy to Treat EBV-driven Lymphomas/Diseases, first trial with adoptive transfer of antigen-specific T memory stem cells for EBV-specific T-cell therapy; insights into fate of these cells after infusion into patients
- 2021– 2024 University Hospital of Basel: Innovation Focus Cell Therapy
- 2021 Propatient Research Grant: Third-Party Donor Registry for Personalized antiviral T-cell Immunotherapeutic
- 2020 – 2024 Swiss National Science Foundation. National Center of Competence in Research (NCCR) AntiResist
- 2018 – 2022 Project Partner Swiss National Science Foundation. Investigator Initiated Clinical Trials (IICT): Using Genetic Risk Factors to Stratify Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia
Research Team
Rajesh Jayachandran, PhD
Research Fellow
Phone +41 61 265 21 14
Email
Claudia Stühler, PhD
Postdoctoral Fellow
Phone +41 61 328 60 17
Email
Nathalie Müller
Doctoral candidate
Phone +41 61 328 67 45
Email